News articles about Boston Scientific (NYSE:BSX) have been trending somewhat positive recently, Accern reports. The research firm scores the sentiment of press coverage by analyzing more than 20 million blog and news sources. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Boston Scientific earned a daily sentiment score of 0.19 on Accern’s scale. Accern also assigned media coverage about the medical equipment provider an impact score of 45.214959345656 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

Here are some of the headlines that may have effected Accern Sentiment’s rankings:

BSX has been the topic of a number of analyst reports. BidaskClub cut Boston Scientific from a “hold” rating to a “sell” rating in a research note on Saturday, August 26th. Royal Bank of Canada reaffirmed a “buy” rating and issued a $31.00 price target on shares of Boston Scientific in a research note on Friday, September 1st. Zacks Investment Research raised Boston Scientific from a “sell” rating to a “buy” rating and set a $33.00 price target on the stock in a research note on Friday, October 20th. Jefferies Group reaffirmed a “hold” rating on shares of Boston Scientific in a research note on Thursday, September 7th. Finally, Canaccord Genuity decreased their price target on Boston Scientific from $36.00 to $35.00 and set a “buy” rating on the stock in a research note on Wednesday, November 29th. One investment analyst has rated the stock with a sell rating, four have assigned a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. Boston Scientific currently has a consensus rating of “Buy” and a consensus target price of $31.03.

Boston Scientific (BSX) traded up $0.16 on Friday, hitting $25.78. The stock had a trading volume of 12,186,964 shares, compared to its average volume of 7,083,045. The company has a quick ratio of 0.50, a current ratio of 0.72 and a debt-to-equity ratio of 0.58. Boston Scientific has a 52-week low of $21.29 and a 52-week high of $29.93. The stock has a market capitalization of $35,304.87, a PE ratio of 21.07, a PEG ratio of 1.98 and a beta of 0.96.

Boston Scientific (NYSE:BSX) last posted its earnings results on Thursday, October 26th. The medical equipment provider reported $0.31 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.31. Boston Scientific had a return on equity of 23.60% and a net margin of 9.55%. The firm had revenue of $2.22 billion for the quarter, compared to analysts’ expectations of $2.21 billion. During the same period in the previous year, the firm earned $0.27 earnings per share. The business’s revenue was up 5.6% compared to the same quarter last year. analysts forecast that Boston Scientific will post 1.25 earnings per share for the current fiscal year.

In related news, EVP Timothy A. Pratt sold 10,000 shares of Boston Scientific stock in a transaction that occurred on Wednesday, November 1st. The stock was sold at an average price of $28.22, for a total transaction of $282,200.00. Following the sale, the executive vice president now directly owns 164,681 shares in the company, valued at $4,647,297.82. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Valley Gold Master Fund L. Sun purchased 408,006 shares of the company’s stock in a transaction that occurred on Tuesday, November 28th. The shares were purchased at an average price of $0.45 per share, for a total transaction of $183,602.70. Insiders have sold 424,698 shares of company stock worth $12,273,553 over the last 90 days. 0.74% of the stock is currently owned by corporate insiders.

ILLEGAL ACTIVITY WARNING: This article was first posted by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this article on another domain, it was stolen and reposted in violation of US and international copyright & trademark law. The legal version of this article can be read at https://www.thecerbatgem.com/2017/12/15/boston-scientific-bsx-receiving-somewhat-favorable-press-coverage-report-finds.html.

Boston Scientific Company Profile

Boston Scientific Corporation is a developer, manufacturer and marketer of medical devices that are used in a range of interventional medical specialties. The Company offers its products by seven businesses: Interventional Cardiology, Cardiac Rhythm Management, Endoscopy, Peripheral Interventions, Urology and Pelvic Health, Neuromodulation, and Electrophysiology.

Insider Buying and Selling by Quarter for Boston Scientific (NYSE:BSX)

Receive News & Stock Ratings for Boston Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Boston Scientific and related stocks with our FREE daily email newsletter.